Drug Trial Radar · NCT05054023
Topical Piroxicam vs Soulagel in the Treatment of Acute Extremity Pain After Emergency Department Discharge
Last checked: Nov 19, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,525
Actual
Start
Oct 21, 2021
Primary completion
Mar 21, 2022
Study completion Mar 21, 2022
Sponsor
- Lead sponsor
- University of MonastirAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute soft tissues injuries are a common complaint for emergency department (ED) visit. RICE and Topical non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to reduce pain and inflammation. Herbal therapy is commonly used to treat pain but few studies assessed its efficacy and tolerability.
Conditions
- Acute Pain
Interventions
Soulagel®Drug
topic gel
Arthrosyl®Drug
topic gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment success resolution of pain with decrease of VAS more than 50% comparing to initial value at 30 minutes following analgesia administrationTime frame: at seven days post ED discharge
- Occurence of severe adverse eventsTime frame: at seven days post ED discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nouira Samir
Monastir, Emergency Department Monastir, Tunisia 5000, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.